Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease.

Abstract

BACKGROUND:

Biogenic amines and monoamine oxidase inhibitors influence peripheral monoamine oxidase enzyme activity in chronic levodopa/dopa decarboxylase inhibitor-treated patients with Parkinson disease. Rasagiline is an irreversible inhibitor of monoamine oxidase B. Safinamide blocks this isoenzyme in a reversible fashion.

OBJECTIVES:

The aim of this study was to determine monoamine oxidase A (plasma) and B (platelets) enzyme activity in long-term levodopa-treated patients without and with additional oral intake of 50- or 100-mg safinamide or 1-mg rasagiline or first-time intake of rasagiline.

RESULTS:

Monoamine oxidase A enzyme activity did not differ between all groups. Patients on rasagiline or safinamide showed lower monoamine oxidase-B enzyme activity compared with patients without monoamine oxidase B inhibitor intake. No impact of the number of previous oral levodopa intakes was found.

DISCUSSION:

Rasagiline and safinamide did not essentially differ in terms of inhibition of monoamine oxidase B despite their different pharmacology regarding reversibility of monoamine oxidase B inhibition. In view of the observed, considerable heterogeneity of enzyme activities, we suggest to determine activities of monoamine oxidase A and B to reduce the risk for tyramine-induced hypertension and the serotonergic syndrome during chronic therapy with rasagiline or safinamide.

• Authors: Thomas Müller, Peter Riederer, Edna Grünblatt
• Journal: Clinical neuropharmacology (Clin Neuropharmacol) 2017 Sep/Oct Vol. 40 Issue 5 Pg. 208-211 ISSN: 1537-162X [Electronic] United States
• PMID: 28682929 (Publication Type: Controlled Clinical Trial, Journal Article)

Chemical References

• Benzylamines
• Indans
• Monoamine Oxidase Inhibitors
• rasagiline
• Levodopa
• safinamide
• Monoamine Oxidase
• Alanine

Topics

• Aged
• Alanine (administration & dosage, analogs & derivatives, pharmacology, therapeutic use)
• Benzylamines (administration & dosage, pharmacology, therapeutic use)
• Humans
• Indans (administration & dosage, pharmacology, therapeutic use)
• Levodopa (therapeutic use)
• Male
• Middle Aged
• Monoamine Oxidase (blood)
• Monoamine Oxidase Inhibitors (administration & dosage, pharmacology, therapeutic use)
• Parkinson Disease (blood, drug therapy, enzymology)